SCHEMBL6749082

SCHEMBL6749082

COC[C@@H]1CCCN1C(=O)c1cc2nccc(Oc3ccc4[nH]c(C)cc4c3F)c2s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 13/20 0.43
PDGFRB P09619 2/20 0.43
TLR8 Q9NR97 2/20 0.42
TLR7 Q9NYK1 2/20 0.42
MET P08581 5/20 0.41
FLT1 P17948 2/20 0.39
PLK4 O00444 1/20 0.39
GAK O14976 1/20 0.39
EPHB6 O15197 1/20 0.39
RIPK2 O43353 1/20 0.39
ERN1 O75460 1/20 0.39
STK10 O94804 1/20 0.39
MAP4K4 O95819 1/20 0.39
CHEK2 O96017 1/20 0.39
ABL1 P00519 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6751165 0.90 KDR (0.45) KDRPDGFRBMETFLT1PLK4
SCHEMBL5838442 0.85 RAB9A (0.42) KDRTLR8TLR7FLT1
SCHEMBL5838156 0.85 RAB9A (0.42) KDRTLR8TLR7FLT1
SCHEMBL5838148 0.85 RAB9A (0.42) KDRTLR8TLR7FLT1
SCHEMBL6751167 0.84 KDR (0.49) KDRPDGFRBMETFLT1PLK4
SCHEMBL6752148 0.84 KDR (0.49) KDRPDGFRBMETFLT1PLK4
SCHEMBL6753406 0.82 KDR (0.40) KDRMETFLT1LRRK2
SCHEMBL6751967 0.80 KDR (0.39) KDRMETFLT1LRRK2
SCHEMBL6750894 0.79 KDR (0.40) KDRTLR8TLR7FLT1
SCHEMBL6632827 0.78 KDR (0.40) KDRTLR8TLR7METFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6833456-B2 Heterocyclic sulfides such as 5-(2-(2R-Hydroxymethyl-pyrrolidine-1-carbonyl)-thieno(3,2-b)pyridin-7 -ylamino)-2-methyl-indole-1-carboxylic acid methylamide, used as angiogenesis inhibitors AGOURON PHARMACEUTICALS, INC. 2004-12-21 US disclosed
US-20040019065-A1 Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use ROMINES WILLIAM HENRY (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019065-A1 Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use CDKN1A, CCNA1, TYMP KDR 62/4885PDGFRB 836/4885TLR8 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.